Inloggen

Login
 
Wachtwoord vergeten?

Onxeo 2019

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
77 Posts, Pagina: « 1 2 3 4 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
rationeel
0
quote:

RW1963 schreef op 23 oktober 2019 19:48:


[...]

I hope so. Bij 2,49 heb ik zelfs ietsje winst ;-)


Moet kunnen:)

En heb ik het ook:)
JosVos
0
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment. Combination patent to be granted in the U.S. until 2036
Bijlage:
rationeel
0
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment It further expands Onxeo’s intellectual property portfolio for AsiDNA™, which now includes
...168... number of patents globally.

Combination patent to be granted in the U.S. until 2036

rationeel
0
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology

Paris (France), November 13, 2019 – 6:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of the results of preclinical studies comparing the efficacy and toxicity of two DNA repair inhibitors: olaparib, a PARP inhibitor, and AsiDNA™, the Company’s first-in-class DDR inhibitor, in the peer-reviewed journal, Frontiers in Oncology. In-vivo models showed that, while both DNA repair inhibitors were effective, only AsiDNA™ could delay resistance to carboplatin without increasing its toxicity.

Françoise BONO, Chief Scientific Officer of Onxeo, commented: "The results of these in-vivo studies highlighted the distinctive characteristics of our clinical stage product candidate, AsiDNA™. Most importantly, these studies show AsiDNA’s™ ability to delay resistance to carboplatin without increasing its toxicity, a critical property that has not previously been observed in anti-cancer agents, including olaparib. In addition, the studies confirmed the overall good safety profile of AsiDNA™. These translational studies, conducted in collaboration with the research laboratory of Marie Dutreix at the Institut Curie, were instrumental in our decision to prioritize the clinical development of AsiDNA™ in combination with chemotherapy. We now look forward to the preliminary data from our ongoing DRIIV-1b Phase 1b clinical study of AsiDNA™ in combination with a reference chemotherapy (carboplatin and paclitaxel), expected in a few weeks."

The original research article, titled “Preclinical studies comparing efficacy and toxicity of DNA repair inhibitors, olaparib and AsiDNA, in treatment of carboplatin resistant tumors,” is currently available on the Frontiers in Oncology website.
Woman in Chains32
1
quote:

RW1963 schreef op 15 april 2019 20:52:


[...]

Helaas geen bodem gezet.

pe26 zit jij er nog in? Wat is jouw mening?



Ik heb vandaag aandelen gekocht. Al een paar keer verlies gehad op trades Onxeo,
maar kijk uit naar voorlopige data DRIIV-1b AsiDNA™ 600 mg + carboplatin + paclitaxel.

En daarna filing of Phase 1b/2 combo study w/ PARPi (Niraparib) begin 2020.

Het PlatON™, proprietary chemistry platform of decoy agonist oligonucleotides kan op termijn haar beloften waarmaken (AsiDNA™ en OX401).

We gaan snel zien of Onxeo de Phase 1b/2 combo study kan gaan opstarten; belangrijk dat voorlopige data van DRIIV-1b studie goed is voor einde jaar.
RW1963
0
quote:

Woman in Chains32 schreef op 20 november 2019 13:08:


[...]


Ik heb vandaag aandelen gekocht. Al een paar keer verlies gehad op trades Onxeo,
maar kijk uit naar voorlopige data DRIIV-1b AsiDNA™ 600 mg + carboplatin + paclitaxel.

En daarna filing of Phase 1b/2 combo study w/ PARPi (Niraparib) begin 2020.

Het PlatON™, proprietary chemistry platform of decoy agonist oligonucleotides kan op termijn haar beloften waarmaken (AsiDNA™ en OX401).

We gaan snel zien of Onxeo de Phase 1b/2 combo study kan gaan opstarten; belangrijk dat voorlopige data van DRIIV-1b studie goed is voor einde jaar.


pe26/Woman in Chains32 thanx
(op het Galapagos forum wordt je wel gemist)
Eurowin
0
quote:

rationeel schreef op 10 januari 2020 11:29:


Eindelijk de bodem gezet?


Dank voor de TIP, Gr en suc6
rationeel
0
UPCOMING EVENTS

BioMed Event 2020 – Paris
January 28, 2020 | 9:00 am – 6:30 pm
Les Salons Hoche - 9, avenue Hoche - 75001 Paris, France

PARP & DDR Inhibitors Summit 2020
January 29, 2020 – January 31, 2020
Revere Hotel Boston Common, Boston, MA - USA
RW1963
0
quote:

rationeel schreef op 10 januari 2020 11:29:


Eindelijk de bodem gezet?


Ik hoop het! In ieder geval vandaag een leuke stijging :-)

(maar ik ben er nog lang niet)
rationeel
0
quote:

RW1963 schreef op 10 januari 2020 18:40:


[...]

Ik hoop het! In ieder geval vandaag een leuke stijging :-)

(maar ik ben er nog lang niet)


Ik ook niet.

Ik heb nog gezocht of ik iets kon vinden, wat deze grote stijging kon verklaren. Maar dat heb ik niet kunnen vinden.

Misschien morgen?

Wel technisch: Het breken van 3! weerstanden.
Stapvoets
1
Hoop dat deze stijging ergens op gebaseerd is. Was wel blij verrast vandaag, maar ben er ook nog lang niet.
Woman in Chains32
2
13 december 2019:

Françoise BONO, Chief Scientific Officer of Onxeo, commented: "The results of these in-vivo studies highlighted the distinctive characteristics of our clinical stage product candidate, AsiDNA™. Most importantly, these studies show AsiDNA’s™ ability to delay resistance to carboplatin without increasing its toxicity, a critical property that has not previously been observed in anti-cancer agents, including olaparib. In addition, the studies confirmed the overall good safety profile of AsiDNA™. These translational studies, conducted in collaboration with the research laboratory of Marie Dutreix at the Institut Curie, were instrumental in our decision to prioritize the clinical development of AsiDNA™ in combination with chemotherapy. We now look forward to the preliminary data from our ongoing DRIIV-1b Phase 1b clinical study of AsiDNA™ in combination with a reference chemotherapy (carboplatin and paclitaxel), expected in a few weeks."



Je zou denken: van de week komen de data los.

Het blijft een kleine studie (DRIIV-1b) in aantal patiënten, maar wel van belang voor verdere doorstart AsiDNA naar mogelijke POC studies + Niraparib (Tesaro).

Onxeo kan een mooi momentum pakken voor....of het wordt weer uien.
Op basis van eerdere data is er veel vertrouwen in AsiDNA.

BioMed Event 2020 – Paris
January 28, 2020 | 9:00 am – 6:30 pm
Les Salons Hoche - 9, avenue Hoche - 75001 Paris, France

PARP & DDR Inhibitors Summit 2020
January 29, 2020 – January 31, 2020
Revere Hotel Boston Common, Boston, MA - USA


www.onxeo.com/wp-content/uploads/2019...
rationeel
0
Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020


The press release in PDF



Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company’s Chief Scientific Officer, Françoise Bono, will present OX401, a next-generation PARP inhibitor (PARPi) of the Company, during an oral presentation at the PARP & DDR Inhibitors Summit 2020 held in Boston, MA on January 29-30, 2020.

“OX401 benefits from our accumulated insight into the unique decoy agonist mechanism already present in our clinical-stage DDR inhibitor AsiDNA™ and we are excited to present this very innovative PARP inhibitor to the world’s most recognized stakeholders in DNA Damage Response,” said Françoise Bono, Chief Scientific Officer of Onxeo. “We are in the process of building a strong preclinical data set for OX401, which was optimized to be potent on both PARP inhibition and STING response and to bypass resistance as well as homologous recombination deficiency requirements, two of the major hurdles faced by PARP inhibitors today.”

OX401 is the second candidate sourced from Onxeo's proprietary platform of decoy agonists, platON™. This new compound was optimized to maintain this unique mechanism of action, while targeting other DNA-binding proteins and other mechanisms involved in tumor growth, such as the immune response. Its properties position OX401 at the crossroads of two of the most active areas in oncology, DNA Damage Response and immunotherapy.
77 Posts, Pagina: « 1 2 3 4 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Onxeo Meer »

Koers 0,422   Verschil -0,01 (-2,54%)
Laag 0,422   Volume 126.511
Hoog 0,442   Gem. Volume 263.844
6 apr 2020 17:35
label premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare